Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype

Authors: Han Sung Kang, Seok Cheol Lee, Young Seung Park, Young Eun Jeon, Jeong Hwa Lee, So-Youn Jung, In Hae Park, Seok Hoon Jang, Hye Min Park, Chong Woo Yoo, Seok Hee Park, Sang Yun Han, Kwang Pyo Kim, Young Hwan Kim, Jungsil Ro, Hark Kyun Kim

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) has been demonstrated to be useful for molecular profiling of common solid tumors. Using recently developed MALDI matrices for lipid profiling, we evaluated whether direct tissue MALDI MS analysis on proteins and lipids may classify human breast cancer samples according to the intrinsic subtype.

Methods

Thirty-four pairs of frozen, resected breast cancer and adjacent normal tissue samples were analyzed using histology-directed, MALDI MS analysis. Sinapinic acid and 2,5-dihydroxybenzoic acid/α-cyano-4-hydroxycinnamic acid were manually deposited on areas of each tissue section enriched in epithelial cells to identify lipid profiles, and mass spectra were acquired using a MALDI-time of flight instrument.

Results

Protein and lipid profiles distinguish cancer from adjacent normal tissue samples with the median prediction accuracy of 94.1%. Luminal, HER2+, and triple-negative tumors demonstrated different protein and lipid profiles, as evidenced by permutation P values less than 0.01 for 0.632+ bootstrap cross-validated misclassification rates with all classifiers tested. Discriminatory proteins and lipids were useful for classifying tumors according to the intrinsic subtype with median prediction accuracies of 80.0-81.3% in random test sets.

Conclusions

Protein and lipid profiles accurately distinguish tumor from adjacent normal tissue and classify breast cancers according to the intrinsic subtype.
Appendix
Available only for authorised users
Literature
2.
go back to reference Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics. 2007, 5 (2): 77-85. 10.1016/S1672-0229(07)60018-7.CrossRefPubMed Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics. 2007, 5 (2): 77-85. 10.1016/S1672-0229(07)60018-7.CrossRefPubMed
3.
go back to reference Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, Mogg M, Schreiber M, Feuerstein I, Huck CW, Stecher G, Bonn GK, Huber LA: Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis. 2006, 27 (8): 1641-1650. 10.1002/elps.200500857.CrossRefPubMed Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, Mogg M, Schreiber M, Feuerstein I, Huck CW, Stecher G, Bonn GK, Huber LA: Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis. 2006, 27 (8): 1641-1650. 10.1002/elps.200500857.CrossRefPubMed
4.
go back to reference Drake RR, Cazares LH, Jones EE, Fuller TW, Semmes OJ, Laronga C: Challenges to developing proteomic-based breast cancer diagnostics. OMICS. 2011, 15 (5): 251-259. 10.1089/omi.2010.0120.CrossRefPubMedPubMedCentral Drake RR, Cazares LH, Jones EE, Fuller TW, Semmes OJ, Laronga C: Challenges to developing proteomic-based breast cancer diagnostics. OMICS. 2011, 15 (5): 251-259. 10.1089/omi.2010.0120.CrossRefPubMedPubMedCentral
5.
go back to reference Hamrita B, Nasr HB, Chahed K, Chouchane L: Proteomics approaches: New Technologies and Clinical Applications in Breast Carcinomas. Gulf J Oncolog. 2011, 1 (9): 36-44. Hamrita B, Nasr HB, Chahed K, Chouchane L: Proteomics approaches: New Technologies and Clinical Applications in Breast Carcinomas. Gulf J Oncolog. 2011, 1 (9): 36-44.
6.
go back to reference Caprioli RM, Farmer TB, Gile J: Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997, 69: 4751-4760. 10.1021/ac970888i.CrossRefPubMed Caprioli RM, Farmer TB, Gile J: Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997, 69: 4751-4760. 10.1021/ac970888i.CrossRefPubMed
7.
go back to reference Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM: Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Nature Med. 2001, 7: 493-496. 10.1038/86573.CrossRefPubMed Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM: Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Nature Med. 2001, 7: 493-496. 10.1038/86573.CrossRefPubMed
8.
go back to reference Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003, 362 (9382): 433-449. 10.1016/S0140-6736(03)14068-8.CrossRefPubMed Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003, 362 (9382): 433-449. 10.1016/S0140-6736(03)14068-8.CrossRefPubMed
9.
go back to reference Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM: Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 2005, 65 (17): 7674-7681.PubMed Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM: Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 2005, 65 (17): 7674-7681.PubMed
10.
go back to reference Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE: Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010, 9 (8): 4123-4130. 10.1021/pr100302b.CrossRefPubMedPubMedCentral Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE: Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010, 9 (8): 4123-4130. 10.1021/pr100302b.CrossRefPubMedPubMedCentral
11.
go back to reference Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007, 99 (11): 838-46. 10.1093/jnci/djk195.CrossRefPubMed Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007, 99 (11): 838-46. 10.1093/jnci/djk195.CrossRefPubMed
12.
go back to reference Cornett DS, Mobley JA, Dias EC, Andersson M, Arteaga CL, Sanders ME, Caprioli RM: A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics. 2006, 5: 1975-1983. 10.1074/mcp.M600119-MCP200.CrossRefPubMed Cornett DS, Mobley JA, Dias EC, Andersson M, Arteaga CL, Sanders ME, Caprioli RM: A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics. 2006, 5: 1975-1983. 10.1074/mcp.M600119-MCP200.CrossRefPubMed
13.
go back to reference Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfler H, Walch A: Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010, 9 (4): 1854-1863. 10.1021/pr901008d.CrossRefPubMed Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfler H, Walch A: Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010, 9 (4): 1854-1863. 10.1021/pr901008d.CrossRefPubMed
14.
go back to reference Bougnoux P, Chajes V, Lanson M, Hacene K, Body G, Couet C, Le Floch O: Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma. Breast Cancer Res Treat. 1992, 20 (3): 185-194.CrossRefPubMed Bougnoux P, Chajes V, Lanson M, Hacene K, Body G, Couet C, Le Floch O: Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma. Breast Cancer Res Treat. 1992, 20 (3): 185-194.CrossRefPubMed
15.
go back to reference Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS: Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer. 2010, 10: 433-10.1186/1471-2407-10-433.CrossRefPubMedPubMedCentral Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS: Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer. 2010, 10: 433-10.1186/1471-2407-10-433.CrossRefPubMedPubMedCentral
16.
go back to reference Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyotylainen T, Kallioniemi O, Iljin K, Oresic M: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011, 71: 3236-3245. 10.1158/0008-5472.CAN-10-3894.CrossRefPubMed Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyotylainen T, Kallioniemi O, Iljin K, Oresic M: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011, 71: 3236-3245. 10.1158/0008-5472.CAN-10-3894.CrossRefPubMed
17.
go back to reference GLOBOCAN 2008 (IARC): Section of Cancer Information (13/4/2011). GLOBOCAN 2008 (IARC): Section of Cancer Information (13/4/2011).
18.
go back to reference Jackson SN, Woods AS: Direct profiling of tissue lipids by MALDI-TOFMS. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877 (26): 2822-2829. 10.1016/j.jchromb.2008.11.033.CrossRefPubMed Jackson SN, Woods AS: Direct profiling of tissue lipids by MALDI-TOFMS. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877 (26): 2822-2829. 10.1016/j.jchromb.2008.11.033.CrossRefPubMed
19.
go back to reference Shanta SR, Zhou LH, Park YS, Kim YH, Kim Y, Kim KP: Binary matrix for MALDI imaging mass spectrometry of phospholipids in both ion modes. Anal Chem. 2011, 83 (4): 1252-1259. 10.1021/ac1029659.CrossRefPubMed Shanta SR, Zhou LH, Park YS, Kim YH, Kim Y, Kim KP: Binary matrix for MALDI imaging mass spectrometry of phospholipids in both ion modes. Anal Chem. 2011, 83 (4): 1252-1259. 10.1021/ac1029659.CrossRefPubMed
20.
go back to reference Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14: 1368-1376. 10.1158/1078-0432.CCR-07-1658.CrossRefPubMed Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14: 1368-1376. 10.1158/1078-0432.CCR-07-1658.CrossRefPubMed
21.
go back to reference Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed
22.
go back to reference Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-Array Tools. Cancer Informatics. 2007, 2: 11-17. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-Array Tools. Cancer Informatics. 2007, 2: 11-17.
23.
go back to reference Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Shin KH, Lee KS, Park IH, Lee S, Kim SW, Kang HS, Ro J: Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010, 120 (3): 627-637. 10.1007/s10549-010-0780-8.CrossRefPubMed Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Shin KH, Lee KS, Park IH, Lee S, Kim SW, Kang HS, Ro J: Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010, 120 (3): 627-637. 10.1007/s10549-010-0780-8.CrossRefPubMed
24.
go back to reference Park YS, Yoo CW, Lee SC, Park SJ, Oh JH, Yoo BC, Paik SS, Lee KG, Jin SY, Kim SC, Kim KP, Kim YH, Choi DH, Kim HK: Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry. Clin Chim Acta. 2011, 412 (21-22): 1978-1982. 10.1016/j.cca.2011.07.008.CrossRefPubMed Park YS, Yoo CW, Lee SC, Park SJ, Oh JH, Yoo BC, Paik SS, Lee KG, Jin SY, Kim SC, Kim KP, Kim YH, Choi DH, Kim HK: Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry. Clin Chim Acta. 2011, 412 (21-22): 1978-1982. 10.1016/j.cca.2011.07.008.CrossRefPubMed
25.
go back to reference Momchilova A, Markovska T, Pankov R: Phospholipid dependence of membrane-bound phospholipase A2 in ras-transformed NIH 3T3 fibroblasts. Biochimie. 1998, 80 (12): 1055-1062. 10.1016/S0300-9084(99)80012-1.CrossRefPubMed Momchilova A, Markovska T, Pankov R: Phospholipid dependence of membrane-bound phospholipase A2 in ras-transformed NIH 3T3 fibroblasts. Biochimie. 1998, 80 (12): 1055-1062. 10.1016/S0300-9084(99)80012-1.CrossRefPubMed
26.
go back to reference Momchilova AB, Petkova DH, Koumanov KS: Phospholipid composition modifications influence phospholipase A2 activity in rat liver plasma membranes. Int J Biochem. 1986, 18: 945-952. 10.1016/0020-711X(86)90076-5.CrossRefPubMed Momchilova AB, Petkova DH, Koumanov KS: Phospholipid composition modifications influence phospholipase A2 activity in rat liver plasma membranes. Int J Biochem. 1986, 18: 945-952. 10.1016/0020-711X(86)90076-5.CrossRefPubMed
27.
go back to reference Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC: Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One. 2009, 4 (11): e7819-7829. 10.1371/journal.pone.0007819.CrossRefPubMedPubMedCentral Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC: Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One. 2009, 4 (11): e7819-7829. 10.1371/journal.pone.0007819.CrossRefPubMedPubMedCentral
28.
go back to reference Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R: Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res. 2008, 10 (3): R48-10.1186/bcr2046.CrossRefPubMedPubMedCentral Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R: Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res. 2008, 10 (3): R48-10.1186/bcr2046.CrossRefPubMedPubMedCentral
29.
go back to reference Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.CrossRefPubMed Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.CrossRefPubMed
Metadata
Title
Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype
Authors
Han Sung Kang
Seok Cheol Lee
Young Seung Park
Young Eun Jeon
Jeong Hwa Lee
So-Youn Jung
In Hae Park
Seok Hoon Jang
Hye Min Park
Chong Woo Yoo
Seok Hee Park
Sang Yun Han
Kwang Pyo Kim
Young Hwan Kim
Jungsil Ro
Hark Kyun Kim
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-465

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine